Eltrombopag Olamine This page contains brief information about eltrombopag olamine and a collection of links to more information about the use of this drug and ongoing clinical trials. US Brand Name(s): | ![](https://webarchive.library.unt.edu/web/20090829224335im_/http://www.cancer.gov/images/spacer.gif) | Promacta | ![](https://webarchive.library.unt.edu/web/20090829224335im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/web/20090829224335im_/http://www.cancer.gov/images/spacer.gif) | FDA Approved: | ![](https://webarchive.library.unt.edu/web/20090829224335im_/http://www.cancer.gov/images/spacer.gif) | Yes |
Eltrombopag olamine is approved by the Food and Drug Administration (FDA) to treat thrombocytopenia (lower-than-normal number of cells in the blood that help blood clots to form). It is used in patients with chronic immune thrombocytopenic purpura (ITP), a condition in which these blood-clotting cells are destroyed by the immune system. This condition is also called idiopathic thrombocytopenic purpura. Eltrombopag olamine is used in certain patients with ITP who have not gotten better with corticosteroids or immunoglobulins, or with surgery to remove the spleen.
Information from the FDA
FDA Approval for Eltrombopag Olamine - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Information from the National Library of Medicine (NLM)
MedlinePlus Information on Eltrombopag Olamine - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied. Clinical TrialsClinical Trials for Eltrombopag Olamine - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |